Programme Hyperlipidemia Academy 2015 .pdf
Nom original: Programme Hyperlipidemia Academy 2015.pdf
Ce document au format PDF 1.6 a été généré par Adobe InDesign CS5 (7.0.4) / Adobe PDF Library 9.9, et a été envoyé sur fichier-pdf.fr le 05/10/2015 à 09:26, depuis l'adresse IP 84.233.x.x.
La présente page de téléchargement du fichier a été vue 766 fois.
Taille du document: 889 Ko (4 pages).
Confidentialité: fichier public
Aperçu du document
4–5 December 2015
Starling Geneva Hotel, Geneva, Switzerland
On behalf of the Scientific Steering Committee, we have the pleasure of inviting you to attend the third annual
Hyperlipidemia Academy, a highly respected forum in Europe for sharing expert knowledge, education and real-world
experience. This event will be held at the Starling Geneva Hotel, Geneva, Switzerland, on 4–5 December 2015.
This stimulating 2-day meeting will bring together over 350 physicians from across Europe. With an agenda developed
by a European panel of experts, this engaging event will give delegates an important opportunity to hear updates on the
latest data and opinions in the management of patients with hypercholesterolemia. Recently published material on the
inhibition of proprotein convertase subtilisin/kexin type 9 (PCSK9) will be considered and discussed with respect to the
potential of newly licensed monoclonal antibodies to help address the needs of patients at high risk of a cardiovascular
event. Throughout the meeting, we will also break out into a number of interactive workshop groups to discuss and
review a series of topical case studies with leading authorities in the field.
The Hyperlipidemia Academy will provide a forum for you to meet a renowned faculty and to establish relationships
with fellow physicians from across Europe.
We look forward to welcoming you to Geneva for what promises to be a highly informative meeting.
Professor Erik Stroes
Professor Alberico Catapano
Friday 4 December 2015
Saturday 5 December 2015
13.30–13.35 Welcome to the 3rd Hyperlipidemia Academy
Bart Molemans (Amgen), François Mach (Switzerland)
13.35–13.45 Steering Committee’s opening remarks
Erik Stroes (The Netherlands)
13.45–14.45 Key PCSK9 data and breaking news
Ulrich Laufs (Germany), Kausik Ray (UK),
Klaus Parhofer (Germany)
14.45–15.15 In LDL-cholesterol we trust
John Chapman (France)
15.55–16.45 Moderated case study workshops – session 1
Eight different case studies will be presented
17.00–17.40 Debate: Lowering LDL-C below 50 mg/dL is
safe and effective – fact or fantasy?
Fact: Kausik Ray
Fantasy: John Betteridge (UK)
17.40–18.10 Diabetic dyslipidemia and CVD
Marja-Riitta Taskinen (Finland)
18.10–18.15 Close of Day 1
Alberico Catapano (Italy)
Transfer to dinner
Welcome to Day 2
Børge Nordestgaard (Denmark),
Luis Masana (Spain)
Statins: the opportunities and challenges
Erik Stroes, Kausik Ray
Hot topics in 2015
John Chapman, Eric Bruckert (France),
Luis Masana, Marja-Riitta Taskinen
11.15–12.00 PCSK9 experience: case studies from
clinical trials to early real-world experience
Ulrich Laufs, Erik Stroes, François Mach
12.15–13.05 Moderated case study workshops – session 2
Eight different cases will be presented
14.00–14.40 Familial hypercholesterolemia:
the need for better management
14.40–15.30 Journal club
A review of three recent publications
15.30–15.55 Using genetics to inform clinical practice
15.55–16.00 Meeting summary and close
Erik Stroes, Alberico Catapano
Amgen (Europe) GmbH
Dammstrasse 23, CH-6300 Zug, Switzerland
© 2015 Amgen Inc. All rights reserved.